Increased nuclear factor-kappaB activation in colitis of interleukin-2-deficient mice

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 4, 1999, Pages 378-385

  Yang, Fajun ^b   De Villiers, Willem J S ^b   Lee, Eun Y ^b   McClain, Craig J ^b   Varilek, Gary W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033215369     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90152-X     Document Type: Article

References (30)

1. 1. Stenson WF. Inflammatory bowel disease. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, editors. Textbook of gastroenterology. Vol 2. Philadelphia: JB Lippincott Company; 1995. p. 1748-806.
2. 2. Fiocchi C, Podolsky DK. Cytokines and growth factors in inflammatory bowel disease. In: Kirsner JB, Shorter RG, editors. Inflammatory bowel disease. Baltimore: Williams and Wilkens; 1995. p. 252-80.
3. 3. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Ann Rev Immunol 1994;12:141-79.
4. 4. May MJ, Ghosh S. Signal transduction through NF-κB. Immunol Today 1998;19:80-8.
5. 5. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Med 1996;2:998-1004.
6. 6. Conner EM, Brand S, Davis JM, Laroux FS, Palombella VJ, Fuseler JW, et al. Proteasome inhibition attenuates nitric-oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997;282:1615-22.
7. 7. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-69.
8. 8. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998;42: 477-84.
9. 9. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:255-61.
10. 10. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 15:98:1010-20.
11. 11. Yang F, de Villiers WJS, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced TNF production and lethality in a murine model. J Nutr 1998;128:2334-40.
12. 12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
13. 13. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
14. 14. Autenrieth IB, Bucheler N, Bohn E, Heinze G, Horak I. Cytokine mRNA expression in intesitnal tissue of interleukin-2 deficient mice with bowel inflammation. Gut 1997; 41:792-800.
15. 15. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-44.
16. 16. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman J, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
17. 17. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of TH1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45Rbhi CD4+ T cells. Immunity 1994;1:553-6.
18. 18. Benditt EP, Ericksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci U S A 1979;76:4092-6.
19. 19. Liao F, Lusis AJ, Berliner J, Fogelman AW, Kindy MS, de Beer MC, de Beer FC. Serum amyloid A protein family; differential induction by oxidized lipids in mouse strains. Arterioscler Thromb 1994 14:1475-9.
20. 20. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997;91:243-52.
21. 21. Stancovski I, Baltimore D. NF-κB activation: the IκB kinase revealed? Cell 1997;91:299-302.
22. 22. LeBail O, Schmidt-Ulrich R, Isreal A. Promotor analysis of the gene encoding the IκB-α/MAD3 inhibitor of NF-κB: positive regulation by members of the rel/NF-κB family. EMBO J 1993;12:5043-9.
23. 23. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 1995;80:573-82.
24. 24. Tran K, Merika M, Thanos D. Distinct functional properties of IκBα and IκBβ. Mol Cell Biol 1997;17:5386-99.
25. 25. Suyang H, Phillips R, Douglas I, Ghosh S. Role of unphosphorylated newly synthesized IκBβ in persistent activation of NF-κB. Mol Cell Biol 1996;16:5444-9.
26. 26. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 70:286-90.
27. 27. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκB-α in mediation of immunosuppression by glucocorticoids. Science 1995;270: 283-6.
28. 28. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
29. 29. Yang F, de Villiers WJS, McClain CJ, Varilek GW. Mesalamine (5-ASA) modulates nuclear factor-κB/ IκB-α activity in caco-2 cells. Gastroenterology 1997;112:A1125.
30. 30. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956-9.